Immunic expects funding to last into late 2027
IMUX•Immunic expects its funding to last into late 2027. Two fully enrolled Phase 3 trials of vidofludimus calcium, involving 2,221 patients, are expected to report top-line results by year-end 2026.
1. Trial and regulatory timeline
The company targets a U.S. regulatory submission for mid-2027, subject to positive trial results, and expects potential approval in 2028.
